Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Kluisbergen – page 79

2 297 clinical trials in Kluisbergen, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Kluisbergen at a glance
2 297
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 297 trials in Kluisbergen

Open in trial search

Partial seizures

Not yet recruiting

Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Narcolepsy

Not yet recruiting

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Oveporexton
  • Sponsor:Takeda Development Center Americas Inc.

Malignant peritoneal neoplasm+1

Not yet recruiting

Maintenance therapy with raludotatug deruxtecan alone or with bevacizumab versus standard care in patients with newly diagnosed advanced ovarian cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Lupus nephritis+2

Not yet recruiting

Phase 2 Open‑Label Trial Assessing Safety and Efficacy of Nebaprubart in Adults with IgA‑Mediated Renal Diseases

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:JJP BIOLOGICS Sp. z o.o.

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Adenocarcinoma gastric+1

Not yet recruiting

Durvalumab with chemotherapy drug combination versus surveillance in patients with low‑risk localized stomach or gastroesophageal junction cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Centre Leon Berard

Renal disorder

Not yet recruiting

Study of Surovatamig and Human IgG4 Kappa Monoclonal Antibody Against CD3 and CD19 in Adults with Antibody-Mediated Kidney Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg4 Kappa Monoclonal Antibody Against Cd3 And Cd19
  • Sponsor:AstraZeneca AB

Colon cancer

Not yet recruiting

Neoadjuvant Pembrolizumab and Porustobart for Resectable pMMR/MSS Colon Cancer: A Phase 2 Study of Efficacy and Safety in Eligible Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Solstice Oncology Inc.

Pulmonary hypertension

Not yet recruiting

Phase 3 Trial Evaluating Inhaled Mosliciguat for Safety, Efficacy, and Exercise Capacity in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mosliciguat
  • Sponsor:Pulmovant Inc.

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

COVID-19+1

Not yet recruiting

Safety and immune response of investigational mRNA vaccine GSKVX000000078664 versus drug combination in adults with flu and COVID-19

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Elasomeran
  • Sponsor:GlaxoSmithKline Biologicals

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Kluisbergen

What the registry says about research in the country

01 Respiratory Virus Research

Comprehensive studies focusing on respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) prevention in older adults. Researchers are evaluating innovative vaccine approaches for these common respiratory pathogens.

  • RSV Vaccine Development
  • Co-administration Studies
  • Elderly Population Protection

Multiple trials are examining vaccine effectiveness and immune responses in adults over 60 years of age.

02 Influenza Prevention

Research examining a novel influenza vaccine in both younger and older adult populations. The studies focus on safety assessment and immune system response evaluation.

  • Vaccine Safety Analysis
  • Immune Response Measurement
  • Cross-age Group Studies

Trials aim to establish optimal dosing while ensuring robust protection against influenza.

03 Urinary Health Initiatives

Clinical research targeting urinary tract infections (UTI), with particular attention to prevention through vaccination. Studies include both male and female participants aged 18-64.

  • UTI Prevention
  • E. coli-specific Protection
  • Vaccine Safety Evaluation

The research focuses on developing preventive measures against common bacterial infections.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.